Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Benzinga

2025/11/04

Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma. The CRISPR genome-...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580924345"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580924345\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580924345?lang=zh_TW&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/03/Gene-editing.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2025-11-04 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580924345","market":"nz","top_or_hot":-1,"title":"Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>","media":"Benzinga","content":"<div>\n<p>Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">网页链接</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2025-11-04 00:48</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today","article_id":"2580924345","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/03/Gene-editing.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/48596655/why-is-crispr-genome-editing-firm-caribou-biosciences-stock-trading-higher-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2580924345","pubTimestamp":1762188480,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Caribou Biosciences Inc.  stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.The CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel , an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma.The cell therapy uses T-cells from a healthy donor, rather than the patient's own cells, to fight cancer.Also Read: FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering. In the study, 64% of patients treated with Caribou's therapy achieved a complete response. The overall response rate was 82%.In recent interactions, the FDA has recommended that the company conduct a randomized, controlled trial in second-line  large B-cell lymphoma  CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy.The company is advancin","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRSP":"CRISPR Therapeutics AG","BK4611":"AI医疗","BK4585":"ETF&股票定投概念","CAR":"安飞士","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4230":"旅客陆运","LU1861558580.USD":"日兴方舟颠覆性创新基金B","CRBU":"Caribou Biosciences","BK4588":"碎股","BK4022":"陆运","BK4539":"次新股","BK4556":"基因编辑"},"translate_title":"为什么CRISPR基因组编辑公司Caribou Biosciences股票今天交易走高>","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1.5,"CAR":0.63,"CRBU":1.5},"content_text":"Caribou Biosciences Inc. (NASDAQ:CRBU) stock surged on Monday. The company said the CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.\nThe CRISPR genome-editing biopharmaceutical company shared preliminary results from its ongoing ANTLER phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, for relapsed or refractory B-cell non-Hodgkin lymphoma.\nThe cell therapy uses T-cells from a healthy donor, rather than the patient's own cells, to fight cancer.\nAlso Read: FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering\nIn the study, 64% of patients treated with Caribou's therapy achieved a complete response. The overall response rate was 82%.\nAt one year, progression-free survival was 51% (patients remain alive without their cancer worsening).\nCaribou said data from this 35-patient cohort further confirmed that the efficacy and durability of vispa-cel are on par with the autologous CAR-T cell therapies.\nIn all patients treated in ANTLER (N=84), vispa-cel has demonstrated a generally well-tolerated safety profile.\nIn recent interactions, the FDA has recommended that the company conduct a randomized, controlled trial in second-line (2L) large B-cell lymphoma (LBCL) CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy.\nThe company intends to follow this approach with its planned pivotal phase 3 trial design, evaluating approximately 250 patients.\nSeparately, Caribou shared the first clinical data from the dose escalation phase of the ongoing CaMMouflage Phase 1 trial of CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in patients with relapsed or refractory multiple myeloma.\nThe company is advancing the program into dose expansion, which it expects to initiate by the end of this year, and it plans to share dose expansion data in 2026.\nOverall response rate was 92%, and complete response rate was 75%. 91% of the patients achieved minimal residual disease (MRD) negativity (no cancer cells were detected).\nCB-011 had a manageable safety profile across all dose levels and lymphodepletion regimens (N=48).\nPrice Action: CRBU stock is up 17.56% at $2.84 at the last check on Monday.\nRead Next:\nPhoto via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}